| ￥4100 | |
| Z05526-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 113.90 kDa (ITGA8) & 83.2 kDa (ITGB1) | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 120-140 kDa (ITGA8) and 100-120 kDa (ITGB1) based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Integrin alpha 8 beta 1 (ITGA8&ITGB1) Heterodimer, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Human Integrin alpha 8 beta 1 is a heterodimeric glycoprotein composed of integrin alpha 8 and integrin beta 1 that mainly expressed in smooth muscle cells. It functions as a receptor for Tenascin, Fibronectin, and Vitronectin and can promote attachment, cell spreading, and neurite outgrowth. |
| Synonyms | ITGA8&ITGB1; ; α8β1; Integrin alpha 8 beta 1; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
